Do analysts recommend ACU or CERS?

Cerus has a consensus price target of $4.00, suggesting a potential upside of 38.89%. Given Cerus' higher probable upside, analysts plainly believe Cerus is more favorable than Acme United. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acme United 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Cerus 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has higher valuation & earnings, ACU or CERS?

Acme United has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Acme United, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acme United $211.60M 1.12 $17.79M $2.38 26.09 Cerus $206.13M 2.82 -$15.63M -$0.03 N/A

Is ACU or CERS more profitable?

Acme United has a net margin of 10.25% compared to Cerus' net margin of -3.06%. Acme United's return on equity of 9.70% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Acme United 10.25% 9.70% 6.10% Cerus -3.06% -10.19% -3.14%

Does the media refer more to ACU or CERS?

In the previous week, Acme United and Acme United both had 7 articles in the media. Acme United's average media sentiment score of 0.81 beat Cerus' score of 0.43 indicating that Acme United is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acme United 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cerus 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend SMTI or ACU?

Sanara MedTech presently has a consensus target price of $35.00, indicating a potential upside of 2.28%. Given Sanara MedTech's higher possible upside, research analysts clearly believe Sanara MedTech is more favorable than Acme United. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sanara MedTech 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80 Acme United 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Which has higher earnings & valuation, SMTI or ACU?

Acme United has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Acme United, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanara MedTech $109.81M 2.86 -$37.56M -$3.59 N/A Acme United $211.60M 1.12 $17.79M $2.38 26.09

Does the media favor SMTI or ACU?

In the previous week, Acme United had 5 more articles in the media than Sanara MedTech. MarketBeat recorded 7 mentions for Acme United and 2 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 1.20 beat Acme United's score of 0.81 indicating that Sanara MedTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanara MedTech 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acme United 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend EMBC or ACU?

Embecta presently has a consensus price target of $11.00, indicating a potential upside of 98.56%. Given Embecta's higher possible upside, equities research analysts clearly believe Embecta is more favorable than Acme United. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Embecta 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60 Acme United 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Which has preferable valuation and earnings, EMBC or ACU?

Embecta has higher revenue and earnings than Acme United. Embecta is trading at a lower price-to-earnings ratio than Acme United, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Embecta $1.08B 0.29 $95.40M $1.48 3.74 Acme United $211.60M 1.12 $17.79M $2.38 26.09

Is EMBC or ACU more profitable?

Acme United has a net margin of 10.25% compared to Embecta's net margin of 8.59%. Acme United's return on equity of 9.70% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Embecta 8.59% -19.25% 10.82% Acme United 10.25% 9.70% 6.10%

Does the media favor EMBC or ACU?

In the previous week, Embecta had 12 more articles in the media than Acme United. MarketBeat recorded 19 mentions for Embecta and 7 mentions for Acme United. Acme United's average media sentiment score of 0.81 beat Embecta's score of 0.03 indicating that Acme United is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Embecta 0 Very Positive mention(s) 0 Positive mention(s) 18 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Acme United 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate OSUR or ACU?

OraSure Technologies currently has a consensus price target of $3.00, indicating a potential downside of 19.79%. Given OraSure Technologies' higher possible upside, analysts clearly believe OraSure Technologies is more favorable than Acme United. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OraSure Technologies 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Acme United 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Does the media favor OSUR or ACU?

In the previous week, Acme United had 6 more articles in the media than OraSure Technologies. MarketBeat recorded 7 mentions for Acme United and 1 mentions for OraSure Technologies. Acme United's average media sentiment score of 0.81 beat OraSure Technologies' score of 0.34 indicating that Acme United is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OraSure Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Acme United 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate RXST or ACU?

RxSight currently has a consensus target price of $8.37, suggesting a potential upside of 37.16%. Given RxSight's higher possible upside, research analysts plainly believe RxSight is more favorable than Acme United. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RxSight 3 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.92 Acme United 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Which has stronger earnings and valuation, RXST or ACU?

Acme United has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Acme United, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RxSight $134.48M 1.89 -$38.94M -$1.13 N/A Acme United $211.60M 1.12 $17.79M $2.38 26.09

Is RXST or ACU more profitable?

Acme United has a net margin of 10.25% compared to RxSight's net margin of -36.80%. Acme United's return on equity of 9.70% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets RxSight -36.80% -17.35% -14.70% Acme United 10.25% 9.70% 6.10%

Does the media prefer RXST or ACU?

In the previous week, Acme United had 3 more articles in the media than RxSight. MarketBeat recorded 7 mentions for Acme United and 4 mentions for RxSight. RxSight's average media sentiment score of 1.11 beat Acme United's score of 0.81 indicating that RxSight is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acme United 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Acme United (ACU) Competitors

$62.10 0.00 (0.00%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$62.29 +0.19 (+0.30%)

As of 07:01 AM Eastern

Compare

ACU vs. CERS, SMTI, EMBC, OSUR, and RXST

Should you buy Acme United stock or one of its competitors? Acme United's main competitors and comparable companies include Cerus (CERS), Sanara MedTech (SMTI), Embecta (EMBC), OraSure Technologies (OSUR), and RxSight (RXST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Acme United compare to Cerus?

Acme United (NYSE:ACU) and Cerus (NASDAQ:CERS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

62.1% of Acme United shares are held by institutional investors. Comparatively, 78.4% of Cerus shares are held by institutional investors. 29.5% of Acme United shares are held by company insiders. Comparatively, 5.3% of Cerus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Acme United and Acme United both had 7 articles in the media. Acme United's average media sentiment score of 0.81 beat Cerus' score of 0.43 indicating that Acme United is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acme United	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cerus	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cerus has a consensus price target of $4.00, suggesting a potential upside of 38.89%. Given Cerus' higher probable upside, analysts plainly believe Cerus is more favorable than Acme United.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acme United	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Acme United has a net margin of 10.25% compared to Cerus' net margin of -3.06%. Acme United's return on equity of 9.70% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acme United	10.25%	9.70%	6.10%
Cerus	-3.06%	-10.19%	-3.14%

Acme United has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Cerus has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market.

Acme United has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Acme United, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acme United	$211.60M	1.12	$17.79M	$2.38	26.09
Cerus	$206.13M	2.82	-$15.63M	-$0.03	N/A

Summary

Acme United beats Cerus on 11 of the 16 factors compared between the two stocks.

How does Acme United compare to Sanara MedTech?

Sanara MedTech (NASDAQ:SMTI) and Acme United (NYSE:ACU) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

8.1% of Sanara MedTech shares are held by institutional investors. Comparatively, 62.1% of Acme United shares are held by institutional investors. 42.0% of Sanara MedTech shares are held by company insiders. Comparatively, 29.5% of Acme United shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Sanara MedTech has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, Acme United has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

Sanara MedTech presently has a consensus target price of $35.00, indicating a potential upside of 2.28%. Given Sanara MedTech's higher possible upside, research analysts clearly believe Sanara MedTech is more favorable than Acme United.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Acme United	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

In the previous week, Acme United had 5 more articles in the media than Sanara MedTech. MarketBeat recorded 7 mentions for Acme United and 2 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 1.20 beat Acme United's score of 0.81 indicating that Sanara MedTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanara MedTech	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acme United	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Acme United has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Acme United, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$109.81M	2.86	-$37.56M	-$3.59	N/A
Acme United	$211.60M	1.12	$17.79M	$2.38	26.09

Acme United has a net margin of 10.25% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Acme United's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-29.15%	29.72%	2.84%
Acme United	10.25%	9.70%	6.10%

Summary

Acme United beats Sanara MedTech on 10 of the 16 factors compared between the two stocks.

How does Acme United compare to Embecta?

Embecta (NASDAQ:EMBC) and Acme United (NYSE:ACU) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Embecta has higher revenue and earnings than Acme United. Embecta is trading at a lower price-to-earnings ratio than Acme United, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.29	$95.40M	$1.48	3.74
Acme United	$211.60M	1.12	$17.79M	$2.38	26.09

Acme United has a net margin of 10.25% compared to Embecta's net margin of 8.59%. Acme United's return on equity of 9.70% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	8.59%	-19.25%	10.82%
Acme United	10.25%	9.70%	6.10%

Embecta pays an annual dividend of $0.04 per share and has a dividend yield of 0.7%. Acme United pays an annual dividend of $0.64 per share and has a dividend yield of 1.0%. Embecta pays out 2.7% of its earnings in the form of a dividend. Acme United pays out 26.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Acme United has increased its dividend for 20 consecutive years. Acme United is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Embecta presently has a consensus price target of $11.00, indicating a potential upside of 98.56%. Given Embecta's higher possible upside, equities research analysts clearly believe Embecta is more favorable than Acme United.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Acme United	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

93.8% of Embecta shares are owned by institutional investors. Comparatively, 62.1% of Acme United shares are owned by institutional investors. 1.3% of Embecta shares are owned by company insiders. Comparatively, 29.5% of Acme United shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Embecta has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Acme United has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

In the previous week, Embecta had 12 more articles in the media than Acme United. MarketBeat recorded 19 mentions for Embecta and 7 mentions for Acme United. Acme United's average media sentiment score of 0.81 beat Embecta's score of 0.03 indicating that Acme United is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	0 Very Positive mention(s)	0 Positive mention(s)	18 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Acme United	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Acme United beats Embecta on 11 of the 19 factors compared between the two stocks.

How does Acme United compare to OraSure Technologies?

OraSure Technologies (NASDAQ:OSUR) and Acme United (NYSE:ACU) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Acme United has a net margin of 10.25% compared to OraSure Technologies' net margin of -43.70%. Acme United's return on equity of 9.70% beat OraSure Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OraSure Technologies	-43.70%	-19.09%	-16.26%
Acme United	10.25%	9.70%	6.10%

OraSure Technologies has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.Comparatively, Acme United has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market.

Acme United has higher revenue and earnings than OraSure Technologies. OraSure Technologies is trading at a lower price-to-earnings ratio than Acme United, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OraSure Technologies	$112.41M	2.29	-$68.73M	-$0.69	N/A
Acme United	$211.60M	1.12	$17.79M	$2.38	26.09

OraSure Technologies currently has a consensus price target of $3.00, indicating a potential downside of 19.79%. Given OraSure Technologies' higher possible upside, analysts clearly believe OraSure Technologies is more favorable than Acme United.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OraSure Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Acme United	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

93.5% of OraSure Technologies shares are held by institutional investors. Comparatively, 62.1% of Acme United shares are held by institutional investors. 4.7% of OraSure Technologies shares are held by insiders. Comparatively, 29.5% of Acme United shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Acme United had 6 more articles in the media than OraSure Technologies. MarketBeat recorded 7 mentions for Acme United and 1 mentions for OraSure Technologies. Acme United's average media sentiment score of 0.81 beat OraSure Technologies' score of 0.34 indicating that Acme United is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OraSure Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acme United	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Acme United beats OraSure Technologies on 12 of the 16 factors compared between the two stocks.

How does Acme United compare to RxSight?

RxSight (NASDAQ:RXST) and Acme United (NYSE:ACU) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Acme United has a net margin of 10.25% compared to RxSight's net margin of -36.80%. Acme United's return on equity of 9.70% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.80%	-17.35%	-14.70%
Acme United	10.25%	9.70%	6.10%

RxSight currently has a consensus target price of $8.37, suggesting a potential upside of 37.16%. Given RxSight's higher possible upside, research analysts plainly believe RxSight is more favorable than Acme United.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
Acme United	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

78.8% of RxSight shares are held by institutional investors. Comparatively, 62.1% of Acme United shares are held by institutional investors. 10.1% of RxSight shares are held by company insiders. Comparatively, 29.5% of Acme United shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Acme United has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Acme United, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	1.89	-$38.94M	-$1.13	N/A
Acme United	$211.60M	1.12	$17.79M	$2.38	26.09

In the previous week, Acme United had 3 more articles in the media than RxSight. MarketBeat recorded 7 mentions for Acme United and 4 mentions for RxSight. RxSight's average media sentiment score of 1.11 beat Acme United's score of 0.81 indicating that RxSight is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acme United	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

RxSight has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, Acme United has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

Summary

Acme United beats RxSight on 11 of the 17 factors compared between the two stocks.

Get Acme United News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACU vs. The Competition

Export

Metric	Acme United	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$236.60M	$5.89B	$7.34B	$24.24B
Dividend Yield	1.02%	1.74%	2.54%	3.71%
P/E Ratio	12.70	25.93	268.95	29.98
Price / Sales	1.12	67.23	597.99	19.97
Price / Cash	10.02	33.51	78.13	32.31
Price / Book	2.27	5.90	13.01	6.75
Net Income	$17.79M	$148.28M	$3.46B	$1.07B
7 Day Performance	2.81%	0.68%	0.97%	-1.29%
1 Month Performance	33.20%	6.26%	3.85%	1.64%
1 Year Performance	55.06%	8.47%	26.48%	17.29%

Acme United Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACU Acme United	1.268 of 5 stars	$62.10 flat	N/A	+55.6%	$236.60M	$211.60M	12.70	650	Insider Trade High Trading Volume
CERS Cerus	2.041 of 5 stars	$2.57 +2.0%	$4.00 +55.6%	+140.5%	$507.84M	$206.13M	N/A	290
SMTI Sanara MedTech	1.7014 of 5 stars	$34.38 +0.4%	$35.00 +1.8%	+11.4%	$313.87M	$103.12M	N/A	60
EMBC Embecta	3.5061 of 5 stars	$4.88 -2.2%	$11.00 +125.4%	-60.6%	$282.73M	$1.08B	3.30	1,850
OSUR OraSure Technologies	0.9988 of 5 stars	$3.88 -3.0%	$3.00 -22.7%	+29.0%	$275.87M	$115.02M	N/A	840

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ACU) was last updated on 8/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acme United (ACU) Competitors